**PRODUCT DATA SHEET**

**D,L-threo-PDMP**

**Catalog No:** 1719  
**Common Name:** D,L-threo-1-Phenyl-2-decanoylamino-3-morpholino-1-propanol • HCl  
**Source:** synthetic  
**Solubility:** ethanol, methanol, chloroform, DMSO  
**CAS No:** 80938-69-8

**Molecular Formula:** C_{23}H_{38}N_{2}O_{3} • HCl  
**Molecular Weight:** 391 + HCl  
**Storage:** -20°C  
**Purity:** TLC: >98%; identity confirmed by MS  
**TLC System:** chloroform/methanol/acetic acid (90:10:10 by Vol.)  
**Appearance:** solid

**Application notes:**

This product is a glucosylceramide synthase inhibitor, an enzyme that is essential for the synthesis of a very large number of different glycolipids that are found in many organisms.\(^1\) PDMP has four possible isomers due to its two chiral centers (D-threo, L-threo, D-erythro, and L-erythro). This product (D,L-threo-PDMP) is a mixture of D-threo (1R,2R) and L-threo (1S,2S). The D-threo isomer has been shown to be the active glucosyl ceramide synthetase inhibitor.\(^2\) However, treatment with the L-threo isomer has been shown to contribute to an increase in the amount of lactosyl ceramide and may have other effects as well.\(^3\) Due to PDMP’s ability to inhibit the joining of ceramides with carbohydrates there can be an accumulation of ceramide in the cells and this can lead to apoptosis. This process has been suggested as a treatment for cancer.\(^4\) In addition to its stereochemistry, the acyl chain of PDMP has a very marked effect on the intensity of the inhibitory action of the molecule. Conduritol beta epoxide (CBE), an inhibitor of beta-glucosidase, and L-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP), an inhibitor of glucosylceramide synthase, can be used to create a model of Gaucher disease and consequently an accumulation of glucosylosine.\(^5\)

**Selected References:**


This product is to be used for research only. It is not intended for drug or diagnostic use, human consumption or to be used in food or food additives. Matreya assumes no liability for any use of this product by the end user. We believe the information, offered in good faith, is accurate.